Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila A Doggrell

Showing results (41-50 of 220) with videos related to

Pageof 22
Sort By:
Expert Opinion on Pharmacotherapy|December 19, 2017
Cardiovascular outcomes with canagliflozin - is it on the CANVAS?Sheila A Doggrell
Expert Opinion on Biological Therapy|February 2, 2020
Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?Sheila A Doggrell
Expert Opinion on Biological Therapy|November 1, 2022
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|April 5, 2022
Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?Sheila A Doggrell
BMC Nursing|April 24, 2023
Follow-up descriptive study of how proportioning marks between coursework and examination affects the performance of students in nursingSheila A Doggrell
Advances in Physiology Education|September 9, 2021
Quantitative study of lecture attendance and the association between this attendance and academic outcomes for nursing and nonnursing students in an introductory pathophysiology courseSheila A Doggrell
BMC Nursing|September 10, 2024
Descriptive study showing the effect of small differences in entry scores on retention and success in six courses in nursingSheila A Doggrell
Expert Opinion on Investigational Drugs|June 14, 2012
More light at the end of the tunnel - apixaban in atrial fibrillationSheila A Doggrell
Expert Opinion on Biological Therapy|November 4, 2024
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|July 27, 2023
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerantSheila A Doggrell
Pageof 22

Showing results (41-50 of 220) with videos related to

Sort By:
Pageof 22
Expert Opinion on Pharmacotherapy|December 19, 2017
Cardiovascular outcomes with canagliflozin - is it on the CANVAS?Sheila A Doggrell
Expert Opinion on Biological Therapy|February 2, 2020
Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?Sheila A Doggrell
Expert Opinion on Biological Therapy|November 1, 2022
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|April 5, 2022
Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?Sheila A Doggrell
BMC Nursing|April 24, 2023
Follow-up descriptive study of how proportioning marks between coursework and examination affects the performance of students in nursingSheila A Doggrell
Advances in Physiology Education|September 9, 2021
Quantitative study of lecture attendance and the association between this attendance and academic outcomes for nursing and nonnursing students in an introductory pathophysiology courseSheila A Doggrell
BMC Nursing|September 10, 2024
Descriptive study showing the effect of small differences in entry scores on retention and success in six courses in nursingSheila A Doggrell
Expert Opinion on Investigational Drugs|June 14, 2012
More light at the end of the tunnel - apixaban in atrial fibrillationSheila A Doggrell
Expert Opinion on Biological Therapy|November 4, 2024
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|July 27, 2023
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerantSheila A Doggrell
Pageof 22